These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30328618)

  • 1. What is pre-fibrotic myelofibrosis and how should it be managed in 2018?
    Curto-Garcia N; Ianotto JC; Harrison CN
    Br J Haematol; 2018 Oct; 183(1):23-34. PubMed ID: 30328618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.
    Barosi G; Rosti V; Bonetti E; Campanelli R; Carolei A; Catarsi P; Isgrò AM; Lupo L; Massa M; Poletto V; Viarengo G; Villani L; Magrini U
    PLoS One; 2012; 7(4):e35631. PubMed ID: 22536419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
    Thiele J; Kvasnicka HM
    Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and management of prefibrotic myelofibrosis.
    Rumi E; Sant'Antonio E; Boveri E; Pietra D; Cavalloni C; Roncoroni E; Astori C; Arcaini L;
    Expert Rev Hematol; 2018 Jul; 11(7):537-545. PubMed ID: 29862872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.
    Buhr T; Hebeda K; Kaloutsi V; Porwit A; Van der Walt J; Kreipe H
    Haematologica; 2012 Mar; 97(3):360-5. PubMed ID: 22058215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis.
    Thiele J; Kvasnicka HM
    Ann Hematol; 2006 Apr; 85(4):226-32. PubMed ID: 16421727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.
    Kamiunten A; Shide K; Kameda T; Ito M; Sekine M; Kubuki Y; Hidaka T; Akizuki K; Tahira Y; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Shimoda H; Yamashita K; Matsuoka H; Shimoda K
    Int J Hematol; 2018 Oct; 108(4):411-415. PubMed ID: 29987745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany.
    Schmidt A; Bernhardt C; Bürkle D; Fries S; Hannig CV; Jentsch-Ullrich K; Josting A; Kreher S; Reiser M; Steinmetz HT; Tesch H; Terner S; Schulte A; Crodel CC; Palandri F; Heidel FH
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7197-7206. PubMed ID: 36884118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis.
    Vachhani P; Loghavi S; Bose P
    Clin Lymphoma Myeloma Leuk; 2024 Jul; 24(7):413-426. PubMed ID: 38341324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2018 Dec; 93(12):1551-1560. PubMed ID: 30039550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet-derived growth factor receptor β (PDGFRβ) immunohistochemistry highlights activated bone marrow stroma and is potentially predictive for fibrosis progression in prefibrotic myeloproliferative neoplasia.
    Méhes G; Tzankov A; Hebeda K; Anagnostopoulos I; Krenács L; Bedekovics J
    Histopathology; 2015 Nov; 67(5):617-24. PubMed ID: 25825163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis.
    Gianelli U; Vener C; Bossi A; Cortinovis I; Iurlo A; Fracchiolla NS; Savi F; Moro A; Grifoni F; De Philippis C; Radice T; Bosari S; Lambertenghi Deliliers G; Cortelezzi A
    Mod Pathol; 2012 Sep; 25(9):1193-202. PubMed ID: 22627739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelofibrosis in chronic myeloproliferative disorders--dynamics and clinical impact.
    Thiele J; Kvasnicka HM
    Histol Histopathol; 2006 Dec; 21(12):1367-78. PubMed ID: 16977587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic myeloproliferative disorders. The new WHO classification].
    Thiele J; Kvasnicka HM
    Pathologe; 2001 Nov; 22(6):429-43. PubMed ID: 11766643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Occurrence of myelofibrosis in individual types of chronic myeloproliferative diseases].
    Adamkov M; Plank L; Szépe P
    Bratisl Lek Listy; 1998 May; 99(5):240-4. PubMed ID: 9673037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
    Barosi G
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
    Gregory SA; Mesa RA; Hoffman R; Shammo JM
    Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.